(Press-News.org) Rockville, Md., February 13, 2013 – With substandard and counterfeit medicines a dangerous and growing problem in the developing world and elsewhere, identifying new technologies to detect such drugs is an urgent matter. In a new study published in the Journal of Pharmaceutical and Biomedical Analysis, scientists from the U.S. Pharmacopeial Convention (USP) evaluated a handheld Raman device's potential to detect counterfeit and substandard medicines. The device, called TruScan®, is currently used to test Active Pharmaceutical Ingredients (API) and finished pharmaceutical products, and it was evaluated for its ability to differentiate among drug products with different APIs, different brands of the same API, and drug products having the same API but of different strengths, with focus on the specificity and precision of the testing. While TruScan could be used successfully in the initial screening for authentication of the identity of certain targeted medicines, it may not be reliable enough to establish whether the medicines are substandard or not. The print version of the study appears in the journal's February issue.
"Thin Layer Chromatography (TLC) test methods, such as Minilab®, which PQM uses on a regular basis to detect counterfeit and substandard medicines, have been in the market for several years. They are quite reliable, but require specific training and the use of chemicals," said Mustapha Hajjou, Ph.D., lead author of the study, and a program manager for USP's Promoting the Quality of Medicines program (PQM), which is funded by USAID. "There is an increased interest in other, 'non-invasive' spectroscopic methods to detect counterfeit medicines, including near-infrared (NIR) and Raman spectroscopy, like the device we tested, and those would undoubtedly be simpler to use. We just have to make sure they produce reliable results for various types of medicines including substandard medicines, and that is what we tried to evaluate with the TruScan device," he explained. USP is a scientific, nonprofit public health organization that sets standards for the quality of medicines, food ingredients and dietary supplements. USP standards are used in more than 140 countries.
Antimalarial medicines artesunate and combination sulfadoxine-pyrimethamine (SP) were used in the evaluation because of their common use and the prevalence of counterfeit and substandard products in markets where malaria is endemic, and because of previous unfavorable reports of testing these products with a Raman device. Ibuprofen and acetyl salicylic acid tablets were also used, due to their wide range of products with different strengths—allowing the scientists to study the device's ability to discriminate between these products. A reference spectrum or signature, reference standard or a formulation (whole tablet) was created first to be compared to the spectra of other samples. Samples testing yielded either a match or fail result.
Results for the evaluation of antimalarials showed that the device's precision depend on the nature and strength of the active pharmaceutical ingredient (API). All medicines tested obtained acceptable precision results although, for some products, the results were well below 100 percent. The low matching results were attributed to high fluorescence masking the Raman signal, which could generate false negative results in authenticating medicines.
In the specificity evaluation, the Raman device successfully differentiated APIs, which would be useful in testing counterfeit finished products containing the wrong API. However, in the comparison with different lots of the same product and the comparison with similar products from different manufacturers, some samples did not match themselves, and the SP samples from four different manufacturers matched the comparator, showing the device is not sufficient to discriminate among these samples.
The device was also evaluated for its ability to detect different strengths of the same API. Acetyl salicylic acid and acetaminophen tablets all matched the comparator product, regardless of the sample strength, showing the device's limitation in possibly detecting substandard medicines from these classes of drugs.
"We concluded that TruScan will likely detect counterfeit medicines that lack API or have the wrong API, but we cannot rely on it to detect substandard medicines. This is especially true in the case of fixed-dose combinations, where one API may have a strong Raman scatter, masking the signal for other APIs. Because most of the effective medicines treating malaria, HIV/AIDS, and tuberculosis are fixed-dose combinations, we need to be very cautious in using this device for assessment of substandard medicines, says Patrick Lukulay, Ph.D., vice president of USP's Global Health Impact Programs and program director for PQM.
###
Funding for the study was provided by USAID. The contents of this study are the responsibility of the PQM program, implemented by USP, and do not reflect the views of USAID or the United States Government. TruScan is a registered mark of Thermo Scientific.
Media inquiries may be directed to: mediarelations@usp.org.
USP – Advancing Public Health Since 1820
The United States Pharmacopeial Convention (USP) is a scientific, nonprofit, standards-setting organization that advances public health through public standards and related programs that help ensure the quality, safety, and benefit of medicines and foods. USP's standards are relied upon and used worldwide. For more information about USP visit http://www.usp.org.
Handheld device for detecting counterfeit and substandard medicines tested by PQM
2013-02-20
ELSE PRESS RELEASES FROM THIS DATE:
Mushroom-supplemented soybean extract shows therapeutic promise for advanced prostate cancer
2013-02-20
(SACRAMENTO, Calif.) — A natural, nontoxic product called genistein-combined polysaccharide, or GCP, which is commercially available in health stores, could help lengthen the life expectancy of certain prostate cancer patients, UC Davis researchers have found.
Paramita GhoshMen with prostate cancer that has spread to other parts of the body, known as metastatic cancer, and who have had their testosterone lowered with drug therapy are most likely to benefit. The study, recently published in Endocrine-Related Cancer, was conducted in prostate cancer cells and in mice.
Lowering ...
Power connects decision makers to the future
2013-02-20
Decision makers who feel powerful and in control of resources are more likely than others to make decisions that will benefit their future selves, according to researchers at the USC Marshall School of Business.
Conversely, those who lack feelings of power tend to prefer smaller immediate gains – those that benefit the present self – to potentially greater benefits in the future, according to "Power and Reduced Temporal Discounting," a research paper by Nathanael Fast, an assistant professor of management and organization at and Priyanka Joshi, a doctoral candidate ...
International space station plays host to innovative infectious disease research
2013-02-20
Performing sensitive biological experiments is always a delicate affair. Few researchers, however, contend with the challenges faced by Cheryl Nickerson, whose working laboratory aboard the International Space Station (ISS) is located hundreds of miles above the Earth, traveling at some 17,000 miles per hour.
Nickerson, a microbiologist at Arizona State University's Biodesign Institute, is using the ISS platform to pursue new research into the effects of microgravity on disease-causing organisms.
Nickerson presented her research findings and charted the course for ...
UCLA study suggests link between untreated depression, response to shingles vaccine
2013-02-20
Can an individual's state of mind effect how well a vaccine may work? In the case of seniors and shingles, the answer is yes.
Reporting in the current online edition of the journal Clinical Infectious Diseases, Dr. Michael Irwin, a professor of psychiatry at the Semel Institute for Neuroscience and Human Behavior at UCLA, demonstrates a link between untreated depression in older adults and decreased effectiveness of the herpes zoster —or shingles — vaccine.
Shingles is a painful, blistering skin rash that can last for months or even years. It's caused by the varicella–zoster ...
BUSM authors propose potential epigenetic mechanisms for improved cancer therapy
2013-02-20
(Boston) – A review article by researchers at Boston University School of Medicine (BUSM) proposes a new epigenetic hypothesis linked to tumor production and novel ideas about what causes progenitor cells to develop into cancer cells. Published in the February 2013 issue of Epigenomics, the article provides examples of how epigenetic drug treatments could be beneficial in treating cancers while also decreasing the likelihood of cancer relapse.
The article was written by researchers at the Boston University Cancer Center. Sibaji Sarkar, PhD, adjunct instructor of medicine ...
Infants in poverty show different physiological vulnerabilities to the care-giving environment
2013-02-20
Some infants raised in poverty exhibit physical traits that make them more vulnerable to poor caregiving, according to new research published in Psychological Science, a journal of the Association for Psychological Science. The combination of physiological vulnerability and poor caregiving may lead these children to show increased problem behaviors later in childhood.
For infants growing up in poverty, the ability to adapt and regulate — both biologically and behaviorally — in response to various environmental pressures seems to be critical for successful development.
To ...
Rewriting a receptor's role
2013-02-20
In a pair of new papers, researchers at the University of California, San Diego School of Medicine and the Royal Netherlands Academy of Arts and Sciences upend a long-held view about the basic functioning of a key receptor molecule involved in signaling between neurons, and describe how a compound linked to Alzheimer's disease impacts that receptor and weakens synaptic connections between brain cells.
The findings are published in the Feb. 18 early edition of the Proceedings of the National Academy of Sciences.
Long the object of study, the NMDA receptor is located ...
IU research: Rock-paper-scissors a parable for cycles in finance, fashion, politics and more
2013-02-20
BLOOMINGTON, Ind. -- Using a grown-up version of the rock-paper-scissors game, Indiana University cognitive scientists offer a new theory of the group dynamics that arise in situations as varied as cycles of fashion, fluctuations of financial markets, eBay bidding wars and political campaign strategies.
In a study written about this week in PLOS ONE, the researchers analyzed situations in which each person's decision depends on what they think other people will decide, looking at the riddle of "what you think I think you think I think."
What they found, said Seth Frey, ...
New compound holds high promise in battling kidney cancer
2013-02-20
RIVERSIDE, Calif. — Chemists at the University of California, Riverside have developed a compound that holds much promise in the laboratory in fighting renal (kidney) cancer.
Named TIR-199, the compound targets the "proteasome," a cellular complex in kidney cancer cells, similar to the way the drug bortezomib, approved by the Food and Drug Administration, targets and inhibits the proteasome in multiple myeloma cells, a cancer coming from bone marrow.
Michael Pirrung, a distinguished professor of chemistry at UC Riverside, announced the development of TIR-199 in a lecture ...
Diagnosis and treatment now possible for osteoarthritic cats
2013-02-20
VIDEO:
Scientists at the University of Montreal's Quebec Research Group in Animal Pharmacology have found a way to recognize and treat osteoarthritis in cats -- a condition that the owner might...
Click here for more information.
Scientists at the University of Montreal's Quebec Research Group in Animal Pharmacology have found a way to recognize and treat osteoarthritis in cats – a condition that the owner might not notice and that can make even petting painful. "Osteoarthritis ...